P219 Dupilumab Is Well Tolerated and Shows Sustained Efficacy in Patients With Asthma: Liberty Asthma Traverse

Wechsler, M.E.; Ford, Linda; Maspero, J.F.; Pavord, I; Langton, David; Domingo, Christian; Papi, A; Bourdin, Arnaud; Watz, Henrik; Amin, Nikhil; Hardin, Megan

doi:10.1016/j.anai.2020.08.116

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In phase II and III studies, dupilumab reduced serum IgE levels [70,71], reduced severe exacerbation rates and improved lung function (table 1) [70][71][72]. An open-label extension study found that by week 96, dupilumab reduced IgE levels by a median of 82% from the parent study baseline [73]. As previously discussed, anti-IgE properties may be indicative of disease modification potential [74].…”

Section: Complete Remission Off Treatment Figurementioning

confidence: 90%

Holy Grail: the journey towards disease modification in asthma

Busse

Menzies‐Gow

2022

Eur Respir Rev

View full text Add to dashboard Cite

At present, there is no cure for asthma, and treatment typically involves therapies that prevent or reduce asthma symptoms, without modifying the underlying disease. A “disease-modifying” treatment can be classed as able to address the pathogenesis of a disease, preventing progression or leading to a long-term reduction in symptoms. Such therapies have been investigated and approved in other indications, e.g. rheumatoid arthritis and immunoglobulin E-mediated allergic disease. Asthma's heterogeneous nature has made the discovery of similar therapies in asthma more difficult, although novel therapies (e.g. biologics) may have the potential to exhibit disease-modifying properties. To investigate the disease-modifying potential of a treatment, study design considerations can be made, including: appropriate end-point selection, length of trial, age of study population (key differences between adults/children in physiology, pathology and drug metabolism) and comorbidities in the patient population. Potential future focus areas for disease-modifying treatments in asthma include early assessments (e.g. to detect patterns of remodelling) and interventions for patients genetically susceptible to asthma, interventions to prevent virally induced asthma and therapies to promote a healthy microbiome. This review explores the pathophysiology of asthma, the disease-modifying potential of current asthma therapies and the direction future research may take to achieve full disease remission or prevention.

show abstract

Section: Complete Remission Off Treatment Figurementioning

confidence: 90%

Holy Grail: the journey towards disease modification in asthma

Busse

Menzies‐Gow

2022

Eur Respir Rev

View full text Add to dashboard Cite

show abstract

Biological Therapy in Refractory Chronic Rhinosinusitis with Nasal Polyp

Yang¹,

Kim²

2022

J Clin Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Chronic rhinosinusitis with nasal polyp (CRSwNP) can be controlled with medication or surgical treatment, yet limitations exist, and biologics can be an effective alternative for uncontrolled severe CRSwNP patients with poor response to traditional medication and multiple surgeries. In order to better understand the role of biologics in CRSwNP, pharmacokinetics and pharmacodynamics of monoclonal antibodies and local, systemic pathophysiology of CRSwNP in blood vessel, sinus mucosa, and nasal polyp are explored and explained in terms of pathomechanism of each biologic.

show abstract

P219 Dupilumab Is Well Tolerated and Shows Sustained Efficacy in Patients With Asthma: Liberty Asthma Traverse

Cited by 2 publications

References 0 publications

Holy Grail: the journey towards disease modification in asthma

Holy Grail: the journey towards disease modification in asthma

Biological Therapy in Refractory Chronic Rhinosinusitis with Nasal Polyp

Contact Info

Product

Resources

About